A Randomized, Double‐Blind, Placebo‐Controlled, Twelve‐Week, Dose‐Ranging Study of Decernotinib, an Oral Selective JAK‐3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis-Reference-Cited by-同舟云学术

A Randomized, Double‐Blind, Placebo‐Controlled, Twelve‐Week, Dose‐Ranging Study of Decernotinib, an Oral Selective JAK‐3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis

Published:2015-01-28 Issue:2 Volume:67 Page:334-343
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis & Rheumatology

Author:

Fleischmann Roy M.¹,Damjanov Nemanja S.²,Kivitz Alan J.³,Legedza Anna⁴,Hoock Thomas⁴,Kinnman Nils⁵

Affiliation:

1. University of Texas Southwestern Medical CenterDallas

2. University of Belgrade School of MedicineBelgradeSerbia

3. Altoona Center for Clinical ResearchDuncansvillePennsylvania

4. Vertex PharmaceuticalsBostonMassachusetts

5. Vertex PharmaceuticalsEysinsSwitzerland

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.38949

Reference30 articles.

1. Developing an effective treatment algorithm for rheumatoid arthritis

2. Diagnosis and management of rheumatoid arthritis;Rindfleisch JA;Am Fam Physician,2005

3. Improved health‐related quality of life with effective disease‐modifying antirheumatic drugs: evidence from randomized controlled trials;Strand V;Am J Manag Care,2008

4. Rheumatoid arthritis

5. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. VX-509 (Decernotinib)-modified tolerogenic dendritic cells alleviate experimental autoimmune neuritis by promoting Th17/Treg rebalance;International Immunopharmacology;2024-09

2. The efficacy and safety of different Janus kinase inhibitors as monotherapy in rheumatoid arthritis: A Bayesian network meta-analysis;PLOS ONE;2024-06-21

3. Unveiling Novel Drug Targets and Emerging Therapies for Rheumatoid Arthritis: A Comprehensive Review;ACS Pharmacology & Translational Science;2024-05-28

4. Significance of m6A in subtype identification, immunological evolution, and therapeutic sensitivity of RA;Immunobiology;2024-01

5. Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story;Annals of the Rheumatic Diseases;2023-11-03